Rimidi Named to 2022 CB Insights’ Digital Health 150 List
Capping off a year of expanded growth, the company’s clinical management platform is recognized amongst the most promising digital health companies for achievements in care coordination and collaboration
ATLANTA -- December 15, 2022 -- Driven in part by the company’s recent and rapid growth and expansion, Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, announced today it has been named to CB Insights’ Digital Health 150 list.
Utilizing the CB Insights platform, the research team selected the top 150 winners from a pool of over 13,000 private companies, including applicants and nominees. Companies were chosen based on factors including R&D activity, proprietary Mosaic scores, market potential, business relationships, investor profile, news sentiment analysis, competitive landscape, team strength, and tech novelty. The research team also reviewed over 3,000 Analyst Briefings submitted by applicants.
"From reimagining clinical care, to leveraging tech like AR/VR to improve surgical training, this year’s Digital Health 150 winners are transforming the future of healthcare with digital technology,” said Brian Lee, SVP of CB Insights’ Intelligence Unit. “This increasingly global cohort, representing more than 18 countries across five continents, is not only driving better patient outcomes, but making healthcare more accessible. We are excited to follow the meaningful impact and continued success of this year’s winners.”
Digital health adoption continues to accelerate, with the digital health market size is expected to hit $1.5 trillion by 2030. As new devices and digital therapeutics come to market, clinicians will need a way to synthesize the growing amounts of data in a meaningful way that impacts patient care. Rimidi's clinical management platform is meeting this need by bringing data from the latest innovations into the clinical workflow and supporting clinicians with guideline and patient specific clinical decision support.
In addition to being recognized on the Digital Health 150 List, Rimidi was also recently named to AVIA Connect’s Top 50 Companies in Remote Patient Monitoring Report. Furthermore, the company’s entry to the 2022 American Medical Informatics Association(AMIA)/HL7 FHIR Applications competition, “Managing Postpartum Hypertension with Rimidi’s FHIR-enabled Cardiometabolic Management Platform” came in second place in this year’s competition.
“I could not be more proud of the entire Rimidi team for our great accomplishment of making this year’s CB Insights’ Digital Health 150 List. The recognition is truly a testament to the work our team is doing to improve care coordination and collaboration for our customers and within the industry at large,” said Lucienne Ide, MD, PhD, Founder and CEO of Rimidi. “Now in our tenth year of business, we’re more committed than ever to furthering our mission of helping clinicians optimize data for better care, and we're ready to hit the ground running in 2023 and beyond.”
For more information on Rimidi, its solutions, and to stay abreast of upcoming news and updates, visit www.rimidi.com.
Recent News & Insights
By implementing Rimidi’s Respiratory Module, which includes integration with Teva’s Digihaler, …
A version of this article first appeared in Chief Healthcare Executive With the pandemic …